Latvija - latvijski - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - metformīna hidrohlorīds - apvalkotā tablete - 850 mg

Latvija - latvijski - Zāļu valsts aģentūra

laboratori guidotti s.p.a., italy - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg

Latvija - latvijski - Zāļu valsts aģentūra

laboratori guidotti s.p.a., italy - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg

Latvija - latvijski - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - metformīna hidrohlorīds - apvalkotā tablete - 850 mg

Latvija - latvijski - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - metformīna hidrohlorīds - apvalkotā tablete - 500 mg

Europska Unija - latvijski - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoāts, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trīskāršās kombinācijas terapija), kā palīglīdzekli, lai diētu un vingrinājumiem, lai uzlabotu glycaemic kontroles pacientiem, ja insulīna ir stabili devu un metformīns vien nenodrošina pietiekamu kontroles glycaemic.

Europska Unija - latvijski - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.

Europska Unija - latvijski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Latvija - latvijski - Zāļu valsts aģentūra

medochemie ltd., cyprus - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Latvija - latvijski - Zāļu valsts aģentūra

medochemie ltd., cyprus - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg